Works matching IS 00099236 AND DT 2020 AND VI 108 AND IP 2
Results: 32
ASCPT News.
- Published in:
- Clinical Pharmacology & Therapeutics, 2020, v. 108, n. 2, p. 178, doi. 10.1002/cpt.1926
- Publication type:
- Article
In This Issue.
- Published in:
- Clinical Pharmacology & Therapeutics, 2020, v. 108, n. 2, p. 171, doi. 10.1002/cpt.1925
- Publication type:
- Article
Induced Pluripotent Stem Cells: From the Bedside to the Bench, and Hopefully Back Again.
- Published in:
- Clinical Pharmacology & Therapeutics, 2020, v. 108, n. 2, p. 173, doi. 10.1002/cpt.1924
- By:
- Publication type:
- Article
Highlights.
- Published in:
- Clinical Pharmacology & Therapeutics, 2020, v. 108, n. 2, p. 176, doi. 10.1002/cpt.1921
- Publication type:
- Article
Off‐Label Therapies for COVID‐19—Are We All In This Together?
- Published in:
- Clinical Pharmacology & Therapeutics, 2020, v. 108, n. 2, p. 182, doi. 10.1002/cpt.1862
- By:
- Publication type:
- Article
Response to "Dose Rationale for Favipiravir Use in Patients Infected With SARS‐CoV‐2".
- Published in:
- Clinical Pharmacology & Therapeutics, 2020, v. 108, n. 2, p. 190, doi. 10.1002/cpt.1878
- By:
- Publication type:
- Article
Response to "Quantitative Clinical Pharmacology INPUT to SARS‐CoV‐2 Therapeutics Should be Based on Robust Data".
- Published in:
- Clinical Pharmacology & Therapeutics, 2020, v. 108, n. 2, p. 189, doi. 10.1002/cpt.1873
- By:
- Publication type:
- Article
Quantitative Clinical Pharmacology Input to SARS‐CoV‐2 Therapeutics Should Be Based on Robust Data.
- Published in:
- Clinical Pharmacology & Therapeutics, 2020, v. 108, n. 2, p. 187, doi. 10.1002/cpt.1872
- By:
- Publication type:
- Article
Chloroquine Dosing Recommendations for Pediatric COVID‐19 Supported by Modeling and Simulation.
- Published in:
- Clinical Pharmacology & Therapeutics, 2020, v. 108, n. 2, p. 248, doi. 10.1002/cpt.1864
- By:
- Publication type:
- Article
Risks of ACE Inhibitor and ARB Usage in COVID‐19: Evaluating the Evidence.
- Published in:
- Clinical Pharmacology & Therapeutics, 2020, v. 108, n. 2, p. 236, doi. 10.1002/cpt.1863
- By:
- Publication type:
- Article
Dose Rationale for Favipiravir Use in Patients Infected With SARS‐CoV‐2.
- Published in:
- Clinical Pharmacology & Therapeutics, 2020, v. 108, n. 2, p. 188, doi. 10.1002/cpt.1877
- By:
- Publication type:
- Article
Clinical Pharmacology Perspectives on the Antiviral Activity of Azithromycin and Use in COVID‐19.
- Published in:
- Clinical Pharmacology & Therapeutics, 2020, v. 108, n. 2, p. 201, doi. 10.1002/cpt.1857
- By:
- Publication type:
- Article
Optimizing Hydroxychloroquine Dosing for Patients With COVID‐19: An Integrative Modeling Approach for Effective Drug Repurposing.
- Published in:
- Clinical Pharmacology & Therapeutics, 2020, v. 108, n. 2, p. 253, doi. 10.1002/cpt.1856
- By:
- Publication type:
- Article
In Genetic Disorders, One Size Does Not Fit All.
- Published in:
- Clinical Pharmacology & Therapeutics, 2020, v. 108, n. 2, p. 185, doi. 10.1002/cpt.1851
- By:
- Publication type:
- Article
Favipiravir: Pharmacokinetics and Concerns About Clinical Trials for 2019‐nCoV Infection.
- Published in:
- Clinical Pharmacology & Therapeutics, 2020, v. 108, n. 2, p. 242, doi. 10.1002/cpt.1844
- By:
- Publication type:
- Article
Treatment of Fabry's Disease With Migalastat: Outcome From a Prospective Observational Multicenter Study (FAMOUS).
- Published in:
- Clinical Pharmacology & Therapeutics, 2020, v. 108, n. 2, p. 326, doi. 10.1002/cpt.1832
- By:
- Publication type:
- Article
Different Strategies to Execute Multi‐Database Studies for Medicines Surveillance in Real‐World Setting: A Reflection on the European Model.
- Published in:
- Clinical Pharmacology & Therapeutics, 2020, v. 108, n. 2, p. 228, doi. 10.1002/cpt.1833
- By:
- Publication type:
- Article
Translational Model‐Informed Approach for Selection of Tuberculosis Drug Combination Regimens in Early Clinical Development.
- Published in:
- Clinical Pharmacology & Therapeutics, 2020, v. 108, n. 2, p. 274, doi. 10.1002/cpt.1814
- By:
- Publication type:
- Article
Clinical Pharmacogenetics Implementation Consortium Guideline (CPIC) for CYP2C9 and Nonsteroidal Anti‐Inflammatory Drugs.
- Published in:
- Clinical Pharmacology & Therapeutics, 2020, v. 108, n. 2, p. 191, doi. 10.1002/cpt.1830
- By:
- Publication type:
- Article
Does In Vitro Potency Predict Clinically Efficacious Concentrations?
- Published in:
- Clinical Pharmacology & Therapeutics, 2020, v. 108, n. 2, p. 298, doi. 10.1002/cpt.1846
- By:
- Publication type:
- Article
Pharmacoepidemiologic Screening of Potential Oral Anticoagulant Drug Interactions Leading to Thromboembolic Events.
- Published in:
- Clinical Pharmacology & Therapeutics, 2020, v. 108, n. 2, p. 377, doi. 10.1002/cpt.1845
- By:
- Publication type:
- Article
CORRIGENDUM: Abstracts of papers, *2020 Annual Meeting, Marriott Marquis, Houston, Texas, March 18–21, 2020.
- Published in:
- Clinical Pharmacology & Therapeutics, 2020, v. 108, n. 2, p. 387, doi. 10.1002/cpt.1829
- Publication type:
- Article
Pharmacogenomic‐Based Decision Support to Predict Adherence to Medications.
- Published in:
- Clinical Pharmacology & Therapeutics, 2020, v. 108, n. 2, p. 368, doi. 10.1002/cpt.1838
- By:
- Publication type:
- Article
Biomarkers and Precision Therapy for Primary Immunodeficiencies: An In Vitro Study Based on Induced Pluripotent Stem Cells From Patients.
- Published in:
- Clinical Pharmacology & Therapeutics, 2020, v. 108, n. 2, p. 358, doi. 10.1002/cpt.1837
- By:
- Publication type:
- Article
Decision Making Under Uncertainty: Comparing Regulatory and Health Technology Assessment Reviews of Medicines in the United States and Europe.
- Published in:
- Clinical Pharmacology & Therapeutics, 2020, v. 108, n. 2, p. 350, doi. 10.1002/cpt.1835
- By:
- Publication type:
- Article
Pharmacogenetic‐Pharmacokinetic Interactions in Drug Marketing Authorization Applications via the European Medicines Agency Between 2014 and 2017.
- Published in:
- Clinical Pharmacology & Therapeutics, 2020, v. 108, n. 2, p. 338, doi. 10.1002/cpt.1834
- By:
- Publication type:
- Article
A Simple Methodology to Differentiate Changes in Bioavailability From Changes in Clearance Following Oral Dosing of Metabolized Drugs.
- Published in:
- Clinical Pharmacology & Therapeutics, 2020, v. 108, n. 2, p. 306, doi. 10.1002/cpt.1828
- By:
- Publication type:
- Article
A Genome‐wide Association Study of Circulating Levels of Atorvastatin and Its Major Metabolites.
- Published in:
- Clinical Pharmacology & Therapeutics, 2020, v. 108, n. 2, p. 287, doi. 10.1002/cpt.1820
- By:
- Publication type:
- Article
Population Analysis of Anidulafungin in Infants to Older Adults With Confirmed or Suspected Invasive Candidiasis.
- Published in:
- Clinical Pharmacology & Therapeutics, 2020, v. 108, n. 2, p. 316, doi. 10.1002/cpt.1831
- By:
- Publication type:
- Article
The Effects of Cruciferous Vegetable‐Enriched Diets on Drug Metabolism: A Systematic Review and Meta‐Analysis of Dietary Intervention Trials in Humans.
- Published in:
- Clinical Pharmacology & Therapeutics, 2020, v. 108, n. 2, p. 212, doi. 10.1002/cpt.1811
- By:
- Publication type:
- Article
Proposed Therapeutic Range of Treosulfan in Reduced Toxicity Pediatric Allogeneic Hematopoietic Stem Cell Transplant Conditioning: Results From a Prospective Trial.
- Published in:
- Clinical Pharmacology & Therapeutics, 2020, v. 108, n. 2, p. 264, doi. 10.1002/cpt.1715
- By:
- Publication type:
- Article
Issue Information.
- Published in:
- Clinical Pharmacology & Therapeutics, 2020, v. 108, n. 2, p. 163, doi. 10.1002/cpt.1524
- Publication type:
- Article